Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › IGF-IR antagonists as adjuvants for treatment of prostate cancer

IGF-IR antagonists as adjuvants for treatment of prostate cancer

US Patent 7972600 · Granted Jul 5, 2011

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Radioconjugates targeting CD33 in the treatment of sarcomas2025
Radioconjugates directed to MHC-complexed antigens in cancer2025
Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-e2024
Anti-PD-L1-anti-TIM-3 bispecific antibodies2022
Checkpoint inhibitor bispecific antibodies2021
Anti-canine platelet derived growth factor receptor alpha antibody2020
Bumped kinase inhibitor compositions and methods for treating cancer2019
Anti-PD-L1-anti-TIM-3 bispecific antibodies2019
PD-L1 antibodies2019
Identifying taxane sensitivity in prostate cancer patients2017
Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatmen2016
Fully human antibodies directed against the human insulin-like growth factor-1 r2011